{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T06:09:05Z","timestamp":1793686145196,"version":"4.5.1"},"reference-count":42,"publisher":"Elsevier BV","issue":"11","license":[{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,7,2]],"date-time":"2024-07-02T00:00:00Z","timestamp":1719878400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"name":"\"R-Pharm\""}],"content-domain":{"domain":["ard.eular.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Annals of the Rheumatic Diseases"],"published-print":{"date-parts":[[2024,11]]},"DOI":"10.1136\/ard-2023-225473","type":"journal-article","created":{"date-parts":[[2024,7,2]],"date-time":"2024-07-02T13:16:20Z","timestamp":1719926180000},"page":"1454-1464","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":18,"title":["Olokizumab plus methotrexate: safety and efficacy over 106 weeks of treatment"],"prefix":"10.1016","volume":"83","clinical-trial-number":[{"clinical-trial-number":"nct02760368","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct02760407","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct02760433","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct03120949","registry":"10.18810\/clinical-trials-gov"}],"author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9872-5282","authenticated-orcid":false,"given":"Eugen","family":"Feist","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6630-1477","authenticated-orcid":false,"given":"Roy M","family":"Fleischmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3005-9439","authenticated-orcid":false,"given":"Saeed","family":"Fatenejad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daria","family":"Bukhanova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sergey","family":"Grishin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2230-5847","authenticated-orcid":false,"given":"Sofia","family":"Kuzkina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Luggen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1598-8360","authenticated-orcid":false,"given":"Evgeniy","family":"Nasonov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mikhail","family":"Samsonov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Josef S","family":"Smolen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1136\/ard-2023-225473_bib1","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1136\/ard-2022-222784","article-title":"Consensus statement on blocking Interleukin-6 receptor and Interleukin-6 in inflammatory conditions: an update","volume":"82","author":"Aletaha","year":"2023","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/ard-2023-225473_bib2","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1056\/NEJMoa2201302","article-title":"Olokizumab versus placebo or adalimumab in rheumatoid arthritis","volume":"387","author":"Smolen","year":"2022","journal-title":"N Engl J Med"},{"key":"10.1136\/ard-2023-225473_bib3","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1136\/annrheumdis-2021-219876","article-title":"Olokizumab, a monoclonal antibody against interleukin 6, in combination with methotrexate in patients with rheumatoid arthritis inadequately controlled by methotrexate: efficacy and safety results of a randomised controlled phase III study","volume":"81","author":"Nasonov","year":"2022","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/ard-2023-225473_bib4","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1002\/art.42347","article-title":"American college of rheumatology\/ EULAR remission criteria for rheumatoid arthritis: 2022 revision","volume":"75","author":"Studenic","year":"2023","journal-title":"Arthritis Rheumatol"},{"key":"10.1136\/ard-2023-225473_bib5","doi-asserted-by":"crossref","first-page":"963","DOI":"10.1136\/annrheumdis-2013-204948","article-title":"Development of EULAR recommendations for the reporting of clinical trial extension studies in rheumatology","volume":"74","author":"Buch","year":"2015","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/ard-2023-225473_bib6","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1007\/s12272-015-0569-8","article-title":"IL-6 inhibitors for treatment of rheumatoid arthritis: past, present, and future","volume":"38","author":"Kim","year":"2015","journal-title":"Arch Pharm Res"},{"key":"10.1136\/ard-2023-225473_bib7","doi-asserted-by":"crossref","first-page":"768","DOI":"10.3899\/jrheum.120687","article-title":"Longterm safety and efficacy of Tocilizumab in patients with rheumatoid arthritis: A cumulative analysis of up to 4.6 years of exposure","volume":"40","author":"Genovese","year":"2013","journal-title":"J Rheumatol"},{"key":"10.1136\/ard-2023-225473_bib8","doi-asserted-by":"crossref","first-page":"R141","DOI":"10.1186\/ar3455","article-title":"Integrated safety in Tocilizumab clinical trials","volume":"13","author":"Schiff","year":"2011","journal-title":"Arthritis Res Ther"},{"key":"10.1136\/ard-2023-225473_bib9","doi-asserted-by":"crossref","first-page":"2287","DOI":"10.1002\/art.10524","article-title":"Frequency of infection in patients with rheumatoid arthritis compared with controls: a population-based study","volume":"46","author":"Doran","year":"2002","journal-title":"Arthritis Rheum"},{"key":"10.1136\/ard-2023-225473_bib10","first-page":"387","article-title":"The risk of hospitalized infection in patients with rheumatoid arthritis","volume":"35","author":"Smitten","year":"2008","journal-title":"J Rheumatol"},{"key":"10.1136\/ard-2023-225473_bib11","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1093\/rheumatology\/kez265","article-title":"Long-term safety of sarilumab in rheumatoid arthritis: an integrated analysis with up to 7 years","volume":"59","author":"Fleischmann","year":"2020","journal-title":"Rheumatology"},{"key":"10.1136\/ard-2023-225473_bib12","first-page":"238","article-title":"Assessment of long-term safety and efficacy of etanercept in a 5-year extension study in patients with rheumatoid arthritis","volume":"29","author":"Klareskog","year":"2011","journal-title":"Clin Exp Rheumatol"},{"key":"10.1136\/ard-2023-225473_bib13","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1136\/annrheumdis-2011-201244","article-title":"Adalimumab: long-term safety in 23 458 patients from global clinical trials in rheumatoid arthritis, juvenile idiopathic arthritis, ankylosing spondylitis, psoriatic arthritis, psoriasis and Crohn's disease","volume":"72","author":"Burmester","year":"2013","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/ard-2023-225473_bib14","doi-asserted-by":"crossref","first-page":"e000491","DOI":"10.1136\/rmdopen-2017-000491","article-title":"Safety and maintenance of response for tofacitinib monotherapy and combination therapy in rheumatoid arthritis: an analysis of pooled data from open-label long-term extension studies","volume":"3","author":"Fleischmann","year":"2017","journal-title":"RMD Open"},{"key":"10.1136\/ard-2023-225473_bib15","doi-asserted-by":"crossref","first-page":"e000887","DOI":"10.1136\/rmdopen-2018-000887","article-title":"Long-term safety and efficacy of sarilumab plus methotrexate on disease activity, physical function and radiographic progression: 5 years of sarilumab plus methotrexate treatment","volume":"5","author":"Genovese","year":"2019","journal-title":"RMD Open"},{"key":"10.1136\/ard-2023-225473_bib16","doi-asserted-by":"crossref","first-page":"456","DOI":"10.3899\/jrheum.161539","article-title":"Two-year efficacy and safety of subcutaneous tocilizumab in combination with disease-modifying Antirheumatic drugs including escalation to weekly dosing in rheumatoid arthritis","volume":"45","author":"Kivitz","year":"2018","journal-title":"J Rheumatol"},{"key":"10.1136\/ard-2023-225473_bib17","doi-asserted-by":"crossref","first-page":"3268","DOI":"10.1093\/rheumatology\/kead062","article-title":"Long-term safety and efficacy of Sarilumab with or without background csDMARDs in rheumatoid arthritis","volume":"62","author":"Burmester","year":"2023","journal-title":"Rheumatology"},{"key":"10.1136\/ard-2023-225473_bib18","doi-asserted-by":"crossref","first-page":"736","DOI":"10.1111\/eci.12799","article-title":"Effects of tocilizumab on neutrophil function and kinetics","volume":"47","author":"Lok","year":"2017","journal-title":"Eur J Clin Invest"},{"key":"10.1136\/ard-2023-225473_bib19","doi-asserted-by":"crossref","first-page":"1321","DOI":"10.1093\/rheumatology\/keu035","article-title":"Effects of IL-6 and IL-6 blockade on neutrophil function in vitro and in vivo","volume":"53","author":"Wright","year":"2014","journal-title":"Rheumatology"},{"key":"10.1136\/ard-2023-225473_bib20","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1016\/j.intimp.2016.03.016","article-title":"Clinical effects of tocilizumab on cytokines and immunological factors in patients with rheumatoid arthritis","volume":"35","author":"Kasama","year":"2016","journal-title":"Int Immunopharmacol"},{"key":"10.1136\/ard-2023-225473_bib21","doi-asserted-by":"crossref","first-page":"e002735","DOI":"10.1136\/rmdopen-2022-002735","article-title":"Safety profile of upadacitinib over 15 000 patient-years across rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis and atopic dermatitis","volume":"9","author":"Burmester","year":"2023","journal-title":"RMD Open"},{"key":"10.1136\/ard-2023-225473_bib22","doi-asserted-by":"crossref","first-page":"7","DOI":"10.3899\/jrheum.171361","article-title":"Safety profile of baricitinib in patients with active rheumatoid arthritis with over 2 years median time in treatment","volume":"46","author":"Smolen","year":"2019","journal-title":"J Rheumatol"},{"key":"10.1136\/ard-2023-225473_bib23","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1093\/rheumatology\/kew329","article-title":"Analysis of haematological changes in tofacitinib-treated patients with rheumatoid arthritis across phase 3 and long-term extension studies","volume":"56","author":"Schulze-Koops","year":"2017","journal-title":"Rheumatology"},{"key":"10.1136\/ard-2023-225473_bib24","doi-asserted-by":"crossref","first-page":"1230","DOI":"10.3899\/jrheum.201183","article-title":"Safety and efficacy of filgotinib: up to 4-year results from an open-label extension study of phase II rheumatoid arthritis programs","volume":"48","author":"Kavanaugh","year":"2021","journal-title":"J Rheumatol"},{"key":"10.1136\/ard-2023-225473_bib25","doi-asserted-by":"crossref","first-page":"1524","DOI":"10.1136\/annrheumdis-2011-200726","article-title":"Risk of incident cardiovascular events in patients with rheumatoid arthritis: a meta-analysis of observational studies","volume":"71","author":"Avina-Zubieta","year":"2012","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/ard-2023-225473_bib26","doi-asserted-by":"crossref","first-page":"1181","DOI":"10.1007\/s00296-020-04616-2","article-title":"The lipid paradox in rheumatoid arthritis: the dark horse of the augmented cardiovascular risk","volume":"40","author":"Venetsanopoulou","year":"2020","journal-title":"Rheumatol Int"},{"key":"10.1136\/ard-2023-225473_bib27","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1002\/art.20878","article-title":"Cardiovascular death in rheumatoid arthritis: a population-based study","volume":"52","author":"Maradit-Kremers","year":"2005","journal-title":"Arthritis Rheum"},{"key":"10.1136\/ard-2023-225473_bib28","doi-asserted-by":"crossref","first-page":"S9","DOI":"10.1016\/j.amjmed.2008.06.011","article-title":"Cardiovascular morbidity and mortality in rheumatoid arthritis","volume":"121","author":"Gabriel","year":"2008","journal-title":"Am J Med"},{"key":"10.1136\/ard-2023-225473_bib29","article-title":"The effect of dmards on cardiovascular outcomes in rheumatoid arthritis: a systematic literature review","author":"Patel","year":"2019","journal-title":"Arthritis Rheumatol"},{"key":"10.1136\/ard-2023-225473_bib30","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1002\/art.41095","article-title":"Cardiovascular safety of tocilizumab versus etanercept in rheumatoid arthritis: a randomized controlled trial","volume":"72","author":"Giles","year":"2020","journal-title":"Arthritis & Rheumatology"},{"key":"10.1136\/ard-2023-225473_bib31","doi-asserted-by":"crossref","first-page":"1042","DOI":"10.1002\/art.40841","article-title":"Cardiovascular safety during treatment with baricitinib in rheumatoid arthritis","volume":"71","author":"Taylor","year":"2019","journal-title":"Arthritis Rheumatol"},{"key":"10.1136\/ard-2023-225473_bib32","doi-asserted-by":"crossref","first-page":"e001395","DOI":"10.1136\/rmdopen-2020-001395","article-title":"Long-term safety of tofacitinib up to 9.5 years: a comprehensive integrated analysis of the rheumatoid arthritis clinical development programme","volume":"6","author":"Cohen","year":"2020","journal-title":"RMD Open"},{"key":"10.1136\/ard-2023-225473_bib33","doi-asserted-by":"crossref","first-page":"e002012","DOI":"10.1136\/rmdopen-2021-002012","article-title":"Long-term safety and efficacy of upadacitinib or adalimumab in patients with rheumatoid arthritis: results through 3 years from the SELECT-COMPARE study","volume":"8","author":"Fleischmann","year":"2022","journal-title":"RMD Open"},{"key":"10.1136\/ard-2023-225473_bib34","doi-asserted-by":"crossref","first-page":"e48","DOI":"10.1161\/ATV.0000000000000147","article-title":"Lipoprotein(a): a genetically determined, causal, and prevalent risk factor for atherosclerotic cardiovascular disease: a scientific statement from the American heart Association","volume":"42","author":"Reyes-Soffer","year":"2022","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1136\/ard-2023-225473_bib35","doi-asserted-by":"crossref","first-page":"2612","DOI":"10.1002\/art.39761","article-title":"Brief report: risk of gastrointestinal perforation among rheumatoid arthritis patients receiving tofacitinib, tocilizumab, or other biologic treatments: GASTROINTESTINAL PERFORATION IN RA","volume":"68","author":"Xie","year":"2016","journal-title":"Arthritis Rheumatol"},{"key":"10.1136\/ard-2023-225473_bib36","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1002\/art.30107","article-title":"The incidence of gastrointestinal perforations among rheumatoid arthritis patients","volume":"63","author":"Curtis","year":"2011","journal-title":"Arthritis Rheum"},{"key":"10.1136\/ard-2023-225473_bib37","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1007\/s40264-018-0651-5","article-title":"Thromboembolism with Janus kinase (JAK) inhibitors for rheumatoid arthritis: how real is the risk","volume":"41","author":"Scott","year":"2018","journal-title":"Drug Saf"},{"key":"10.1136\/ard-2023-225473_bib38","doi-asserted-by":"crossref","first-page":"1917","DOI":"10.1136\/annrheumdis-2015-208426","article-title":"Comparison of adding tocilizumab to methotrexate with switching to tocilizumab in patients with rheumatoid arthritis with inadequate response to methotrexate: 52-week results from a prospective","volume":"75","author":"Kaneko","year":"2016","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/ard-2023-225473_bib39","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1136\/annrheumdis-2013-204761","article-title":"Clinical, radiographic and immunogenic effects after 1 year of tocilizumab-based treatment strategies in rheumatoid arthritis: the ACT-RAY study","volume":"73","author":"Dougados","year":"2014","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/ard-2023-225473_bib40","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1136\/annrheumdis-2014-206106","article-title":"Evaluating drug-free remission with abatacept in early rheumatoid arthritis: results from the phase 3B, multicentre, randomised, active-controlled AVERT study of 24 months, with a 12-month, double-blind treatment period","volume":"74","author":"Emery","year":"2015","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/ard-2023-225473_bib41","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1002\/art.21519","volume":"54","author":"Breedveld","year":"2006","journal-title":"Arthritis Rheum"},{"key":"10.1136\/ard-2023-225473_bib42","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1136\/ard-2022-223356","article-title":"EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2022 update","volume":"82","author":"Smolen","year":"2023","journal-title":"Ann Rheum Dis"}],"container-title":["Annals of the Rheumatic Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0003496724665398?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0003496724665398?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/ard-2023-225473","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,14]],"date-time":"2025-02-14T03:51:34Z","timestamp":1739505094000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0003496724665398"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11]]},"references-count":42,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2024,11]]}},"alternative-id":["S0003496724665398"],"URL":"https:\/\/doi.org\/10.1136\/ard-2023-225473","relation":{},"ISSN":["0003-4967"],"issn-type":[{"value":"0003-4967","type":"print"}],"subject":[],"published":{"date-parts":[[2024,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Olokizumab plus methotrexate: safety and efficacy over 106 weeks of treatment","name":"articletitle","label":"Article Title"},{"value":"Annals of the Rheumatic Diseases","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1136\/ard-2023-225473","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2024 \u00a9 Author(s) (or their employer(s)) 2024. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by Elsevier Inc on behalf of EULAR. Published by Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}